MX2023014418A - Metodos para tratar las convulsiones inducidas por toxinas neurotóxicas. - Google Patents
Metodos para tratar las convulsiones inducidas por toxinas neurotóxicas.Info
- Publication number
- MX2023014418A MX2023014418A MX2023014418A MX2023014418A MX2023014418A MX 2023014418 A MX2023014418 A MX 2023014418A MX 2023014418 A MX2023014418 A MX 2023014418A MX 2023014418 A MX2023014418 A MX 2023014418A MX 2023014418 A MX2023014418 A MX 2023014418A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- induced seizures
- nerve agent
- treating nerve
- treating
- Prior art date
Links
- 206010010904 Convulsion Diseases 0.000 title 1
- 210000005036 nerve Anatomy 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZXFRFPSZAKNPQQ-YTWAJWBKSA-N tezampanel Chemical compound C([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)O)CC=1N=NNN=1 ZXFRFPSZAKNPQQ-YTWAJWBKSA-N 0.000 abstract 1
- 229950000075 tezampanel Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208885P | 2021-06-09 | 2021-06-09 | |
| PCT/US2022/032783 WO2022261287A1 (en) | 2021-06-09 | 2022-06-09 | Methods of treating nerve agent-induced seizures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014418A true MX2023014418A (es) | 2024-02-13 |
Family
ID=84425551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014418A MX2023014418A (es) | 2021-06-09 | 2022-06-09 | Metodos para tratar las convulsiones inducidas por toxinas neurotóxicas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277696A1 (enExample) |
| EP (1) | EP4352047A4 (enExample) |
| JP (1) | JP2024521430A (enExample) |
| KR (1) | KR20240022544A (enExample) |
| CN (1) | CN117836284A (enExample) |
| AU (1) | AU2022291138A1 (enExample) |
| CA (1) | CA3222575A1 (enExample) |
| IL (1) | IL309097A (enExample) |
| MX (1) | MX2023014418A (enExample) |
| WO (1) | WO2022261287A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1511741B1 (en) * | 2002-04-26 | 2012-12-26 | Eli Lilly And Company | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics |
| US11045462B2 (en) * | 2016-06-14 | 2021-06-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
-
2022
- 2022-06-09 KR KR1020247000572A patent/KR20240022544A/ko active Pending
- 2022-06-09 CN CN202280052288.XA patent/CN117836284A/zh active Pending
- 2022-06-09 US US18/566,735 patent/US20240277696A1/en active Pending
- 2022-06-09 MX MX2023014418A patent/MX2023014418A/es unknown
- 2022-06-09 IL IL309097A patent/IL309097A/en unknown
- 2022-06-09 JP JP2023575935A patent/JP2024521430A/ja active Pending
- 2022-06-09 EP EP22821009.2A patent/EP4352047A4/en active Pending
- 2022-06-09 AU AU2022291138A patent/AU2022291138A1/en active Pending
- 2022-06-09 CA CA3222575A patent/CA3222575A1/en active Pending
- 2022-06-09 WO PCT/US2022/032783 patent/WO2022261287A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL309097A (en) | 2024-02-01 |
| WO2022261287A1 (en) | 2022-12-15 |
| JP2024521430A (ja) | 2024-05-31 |
| KR20240022544A (ko) | 2024-02-20 |
| CN117836284A (zh) | 2024-04-05 |
| EP4352047A4 (en) | 2025-04-16 |
| EP4352047A1 (en) | 2024-04-17 |
| US20240277696A1 (en) | 2024-08-22 |
| AU2022291138A1 (en) | 2023-12-07 |
| CA3222575A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| GEAP202315648A (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2022007276A (es) | Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas. | |
| MA44612B1 (fr) | Méthodes de traitement de cancers pédiatriques | |
| MX2022001863A (es) | Metodos para tratar los tumores del estroma gastrointestinal. | |
| MX2025005792A (es) | Combinaciones farmaceuticas y usos de las mismas | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2025004532A (es) | Método para tratar el cáncer | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| WO2022173888A8 (en) | Pharmaceutically acceptable salts of psilocin and uses thereof | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| EP4353317A3 (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| EP1177791A3 (en) | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | |
| WO2023081482A9 (en) | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases | |
| MA29722B1 (fr) | Schema posologique pour le prasugrel | |
| TW200639159A (en) | Treatment of pain | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |